Drug Encapsulated Lipid-Polymeric Nanohybrid as a Chemo-therapeutic Platform of Cancer

Show simple item record

dc.contributor.author Kumar, Rahul
dc.contributor.author Ranjan Srivastava, Vinish
dc.contributor.author Mahapatra, Supratim
dc.contributor.author Dkhar, Daphika S.
dc.contributor.author Kumari, Rohini
dc.contributor.author Darshna
dc.contributor.author Prerna, Kumari
dc.contributor.author Dubey, Vikash Kumar
dc.contributor.author Chandra, Pranjal
dc.date.accessioned 2024-02-05T06:39:50Z
dc.date.available 2024-02-05T06:39:50Z
dc.date.issued 2023-01-16
dc.identifier.issn 22067418
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/2808
dc.description This paper published with affiliation IIT (BHU), Varanasi in Open Access Mode. en_US
dc.description.abstract The focus of this research is to design a bioengineered drug delivery vehicle that is efficient in anti-cancer drug delivery in a controlled manner. The experimental work focuses on constructing a methotrexate-loaded nano lipid polymer system (MTX-NLPHS) that can transport methotrexate (MTX) in MCF-7 cell lines in a controlled manner through endocytosis via phosphatidylcholine. In this experiment, MTX is embedded with polylactic-co-glycolic acid (PLGA) in phosphatidylcholine, which acts as a liposomal framework for regulated drug delivery. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and dynamic light scattering (DLS) were utilized to characterize the developed nanohybrid system. The particle size and encapsulation efficiency of the MTX-NLPHS were found to be 198 ± 8.44 nm and 86.48 ± 0.31 %, respectively, which is suitable for biological applications. The polydispersity index (PDI) and zeta potential of the final system were found to be 0.134 ± 0.048 and-28 ± 3.50 mV, respectively. The lower value of PDI showed the homogenous nature of the particle size, whereas higher negative zeta potential prevented the system from agglomeration. An in vitro release kinetics was conducted to see the release pattern of the system, which took 250 h for 100% drug release This kind of system may carry the drug for a long time in the circulatory system and prevent the drug discharge. Other cell culture assays such as 3-(4, 5-dimethyl thiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) and reactive oxygen species (ROS) monitoring were used to see the effect of inducers on the cellular system. MTT assay showed cell toxicity of MTX-NLPHS reduced at the lower concentration of the MTX, however, toxicity increased at the higher concentration of the MTX as compared to free MTX. ROS monitoring c revealed more scavenging of ROS using MTX-NLPHS as compared to free MTX. Confocal microscopy suggested the MTX-NLPHS induced more nuclear elongation with cell shrinkage comparatively. en_US
dc.language.iso en en_US
dc.publisher Ivyspring International Publisher en_US
dc.relation.ispartofseries Nanotheranostics;7
dc.subject drug delivery en_US
dc.subject lipid en_US
dc.subject MCF-7 cells en_US
dc.subject methotrexate en_US
dc.subject nanohybrid system en_US
dc.subject theranostics en_US
dc.title Drug Encapsulated Lipid-Polymeric Nanohybrid as a Chemo-therapeutic Platform of Cancer en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search in IDR


Advanced Search

Browse

My Account